Genetic Testing for Alzheimer Disease, Practical and Ethical Issues
Arch Neurol 54:1226-1229, Roses,A.D., 1997
Apolipoprotein E Genotyping in Alzheimer's Disease
Lancet 347:1091-1095, Tanzi,R.,et al, 1996
Statement of Use of Apolipoprotein E Testing for Alzheimer Disease
JAMA 274:1627-1629, Farrer,L.A.,et al, 1995
Apoliprprotein E E4 Allele & the Lifetime Risk of Alzheimer's Disease:What Physicians Know, & What They Should Know
Arch Neurol 52:1074-1079, Seshadri,S.,et al, 1995
Legal and Ethical Implications in the Evaluation and Management of Sports-Related Concussion
Neurol 83:352-359, Kirschen, M.P.,et al, 2014
Should Asymptomatic Patients with Hereditary Haemorrhagic Telangiectasia (HHT) be Screened for Cerebral Vascular Malformations? Data from 22 061 years of HHT Patient Life
JNNP 74:743-748, Easey,A.J.,et al, 2003
Current Concepts in Mild Cognitive Impairment
Arch Neurol 58:1985-1992, Petersen,R.C.,et al, 2001
The Clinical Introduction of Genetic Testing for Alzheimer Disease, An Ethical Perspective
JAMA 277:832-836, Post,S.G.,et al, 1997
Practice Parameter:Genetic Testing Alert
Pract Comm Genet Testing Task Force AAN, Neurol 47:1343-13441996., , 1996
Attitudes of Mothers to Neonatal Screening for Duchenne Muscular Dystrophy
BMJ 300:1112, Smith,R.A.,et al, 1990
Predictive Testing for Huntington's Disease, Progress and Problems
BMJ 298:404-405, 1989, Harper,P.S.&Morris,M.J., 1989